IMpact—RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics1998; 102: 531–7.
2.
PREVENT study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics1997; 99: 93–9.
JoffeSRayTEscobarGJBlackSLieuT. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics1999; 104: 419–27.
5.
MarchettiALauHMagarRWangLDevercelliG. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings. Clin Ther1999; 21: 752–66.
6.
StevensTPSinkinRAHallCBManiscalcoWMMcConnochieKM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med2000; 154: 55–61.
7.
ThomasMBedford-RussellASharlandM. Hospitalisation for RSV infection in ex-preterm infants — Implications for use of RSV immune globulin. Arch Dis Child2000; 83: 122–7.
